In recent years, improved diagnosis of prostate cancer has allowed the development of focal therapy, in order to reduce the morbidity of treatments. Our study assesses the medium-term oncological and functional results of FocalOne® HIFU treatment in localized prostate cancer.
This is a retrospective, multicentre study including patients with low- or intermediate-risk localized prostate cancer treated with Focal one HIFU between November 2014 and December 2019. The primary endpoint was the retreatment rate and subgroup analyses were performed to identify predictive factors of retreatment.
One hundred and thirty-seven patients were included with a median follow-up of 25.5 months. Seventy percent of patients had clinical stage T2, 64% had an ISUP score of 2 or 3 on initial biopsies and 38% were treated with hemi-ablation. Follow-up biopsies were performed in 76.6% of patients during follow-up with 21.8% having clinically significant cancers. The retreatment rate at 24 months was 37.2%, with positive biopsies being the primary criterion for retreatment. Patients with a PSA>8ng/mL had a significantly higher retreatment rate. Finally, morbidity remained acceptable with 5.8% of patients requiring reoperation for complications and 21% for de novo erectile dysfunction.
Our results are in agreement with those of the literature, seeming to indicate a lower morbidity of the focal treatment by HIFU compared to the radical treatments while offering an acceptable oncological control. Prospective randomized trials are ongoing.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2023 Sep 26 [Epub ahead of print]
C Debard, G Margue, C Klein, A Rompré-Brodeur, G Marcq, H Bensadoun, G Robert, M Anidjar, F Bladou
Service d'urologie, CHU de Pellegrin, Bordeaux, France. Electronic address: ., Service d'urologie, CHU de Pellegrin, Bordeaux, France., Department of Surgery (Division of Urology), Mc Gill University Health Center, Montreal, Canada., Service d'urologie, hôpital Claude-Huriez, CHU de Lille, Lille, France.